We are studying whether duvelisib can improve outcomes for patients with relapsed or refractory nodal T cell lymphoma. This trial compares its effects to standard treatments like gemcitabine or bendamustine.
Health conditions and diseases that the clinical trial is designed to study and treat.
Refractory Adult T-cell Lymphoma is a type of cancer that affects the T-cells, a kind of white blood cell, and does not respond to standard treatments. It can lead to symptoms such as swollen lymph nodes, fever, weight loss, and skin rashes.
Relapsed/Refractory Nodal T Cell Lymphoma with T Follicular Helper (TFH) phenotype is a rare type of lymphoma that occurs when the disease returns or does not respond to treatment, characterized by specific T-cell abnormalities. Symptoms may include swollen lymph nodes, fever, and fatigue.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
